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Background   While the importance of physical factors in the 
maintenance and regeneration of bone tissue has been recognized 
for many years and the mechano-sensitivity of bone cells is well 
established, there is increasing evidence that body fat constitutes 
an independent risk factor for complications in bone fracture 
healing  and  aseptic  loosening  of  implants. Although  mechani-
cal causes have been widely suggested, we hypothesized that the 
osteogenic mechano-response of human mesenchymal stem cells 
(hMSCs) may be altered in obese patients. 
Methods      We  determined  the  phenotypic  and  genotypic 
response of undifferentiated hMSCs of 10 donors to cyclic tensile 
strain (CTS) under controlled in vitro conditions and analyzed 
the potential relationship relevant to the donor’s anthropomor-
phometric and biochemical parameters related to donor’s fat and 
bone metabolism. 
Results and interpretation   The osteogenic marker genes were all 
statistically significantly upregulated by CTS, which was accom-
panied by a significant increase in cell-based ALP activity. Linear 
correlation analysis revealed that there was a significant correla-
tion between phenotypic CTS response and the body mass index 
of the donor (r = –0.91, p < 0.001) and phenotypic CTS response 
was also significantly related to leptin levels (r = –0.68) and estra-
diol levels (r = 0.67) within the bone marrow microenvironment 
of the donor. Such an upstream imprinting process mediated by 
factors tightly related to the donor’s fat metabolism, which ham-
pers the mechanosensitivity of hMSCs in obese patients, may be 
of pathogenetic relevance for the complications associated with 
obesity that are seen in orthopedic surgery. 

With its increasing prevalence in the western world, obesity 
is causing an increase in the socioeconomic burden due to its 
harmful consequences, including its effects on the musculo-
skeletal system (Anandacoomarasamy et al. 2007). Obesity 
appears to be an independent risk factor for increased fracture 
risk (Strotmeyer et al. 2005, Leslie et al. 2007) and complica-
tions in fracture healing (nonunions) (Green et al. 2005, Col-
lman et al. 2006, Hofmann et al. 2008), as well as for radio-
logical  and/or  clinical  implant  failure  following  total  joint 
replacement  (Ranawat  and  Boachie-Adjei  1988,  Stern  and 
Insall 1990, Smith et al. 1992, Griffin et al. 1998, Winiarsky et 
al. 1998, Vazquez-Vela et al. 2003, Foran et al. 2004, Berend 
et al. 2005, Amin et al. 2006, Gillespie and Porteous 2007). 
While  mechanical  reasons  (due  to  “overload”)  have  been 
widely suggested, our knowledge about the pathogenesis at 
the cellular level is still very limited. 
The ability of hMSCs to differentiate into several mesen-
chymal cell lineages including the osteoblast lineage plays a 
key role in skeletogenesis and bone regeneration throughout 
life, and biological factors such as cell recruitment, prolifera-
tion, and differentiation have been considered to be critical 
in this regard. However, the differentiation of hMSCs is a 
highly programmed lineage-specific process (Kulterer et al. 
2007) triggered by microenvironmental factors including hor-
mones, cytokines, and growth factors (Tuan et al. 2003)—but 
importantly, also by biomechanical conditions. Indeed, it has 
been shown recently that tensile forces will not only support 
but rather inherently induce the osteogenic differentiation of 
undifferentiated hMSCs under appropriate in vitro conditions 
(Friedl et al. 2007, Mirza et al. 2007). 
Several authors have considered the importance of the host 
microenvironment  in  the  differentiation  process  of  hMSCs 
(Kuznetsov et al. 1997, Caplan et al. 1998), although the clini-
cal relevance of donor-related variability still remains elusive. 
For example, some studies have shown that the functional 
characteristics of hMSCs may be profoundly affected under 
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Mendes et al. 2002), as was also reported for alcohol-induced 
osteonecrosis (Suh et al. 2005) and osteoarthritis (Lisignoli 
et al. 2004), thus suggesting that hMSCs may have a criti-
cal role in the pathogenesis of these diseases. With regard to 
the  obesity-associated  incidence  previously  mentioned,  we 
hypothesized  that  the  initial  osteogenic  mechano-response 
of  undifferentiated  hMSCs  may  be  profoundly  affected  by 
physiological conditions related to the donor’s fat metabolism 
(the null hypothesis being that there are no differences in the 
osteogenic response of hMSCs between obese and non-obese 
donors). 
Material and methods
Experimental design
Bone marrow-derived hMSCs were isolated from 5 female 
and 5 male age-matched donors undergoing elective ortho-
pedic  surgery.  To  obtain  cells  in  an  undifferentiated  state, 
hMSCs were expanded under standard culture conditions for 
cell growth, which was recently demonstrated to keep the cells 
in an undifferentiated state up to passage 10 (Kulterer et al. 
2007). In addition, the cells were seeded at low (subconfluent) 
cell density to minimize contact inhibition and spontaneous 
differentiation. In an effort to eliminate possible confound-
ing factors that might affect cell differentiation unrelated to 
mechanical load, the individual response of undifferentiated 
hMSCs to cyclic tensile strain (CTS) was determined using a 
two-armed study design (strained vs. unstrained under other-
wise equal in vitro conditions). Mechanical stimulation was 
applied with a computer-assisted 4-point bending device, for 
which uniaxial elongation has been shown to be transferred 
properly to cell monolayers (Neidlinger-Wilke et al. 2001). 
The magnitude of tensile strain was restricted to a maximum 
of 3,000 microstrain (µE) in order to avoid a pathological 
response that has been found previously in monolayer culture 
systems due to the application of supra-physiological strains 
(Murray and Rushton 1990). 
Phenotypic  effects  were  characterized  by  analyzing  cell 
numbers, cell viability, and ALP activity. The mRNA levels 
of marker genes for early osteogenic differentiation (RUNX2, 
ALPL, SPARC, SPP1), protein synthesis (COL1A1), and cell 
cycle  (MKI67)  were  determined  by  real-time  RT-PCR.  To 
investigate donor-related variability affecting the osteogenic 
potential of hMSCs, linear correlation analysis was performed 
between  the  functional  characteristics  and  donor-specific 
physiological characteristics, including various biochemical 
indices for donor’s bone and fat metabolism.
Subjects
The study protocol was approved by the local Institutional 
Review Board (control no. 12-091) and informed consent was 
obtained from all subjects. Exclusion criteria included a his-
tory of myelogenous disease, a current history of neoplasm, or 
infections. All patients had normal renal function (serum urea, 
serum creatinine, and creatinine clearance) and did not suffer 
from any conditions known to seriously affect bone metabo-
lism (rheumatoid arthritis, morbus Paget, diabetes mellitus) 
or associated with severe osteoporosis (i.e. ongoing steroid 
intake, anti-resorptive or bone anabolic treatment). 
MSC isolation and cyclic tensile strain (CTS)
Cell  isolation  and  expansion  was  performed  as  previously 
described (Friedl et al. 2007). Briefly, less than 10 mL heparin-
ized bone marrow aspirate was harvested from the iliac crest at 
the start of elective surgery. Mononuclear cells were isolated 
by gradient centrifugation and expanded under standard con-
ditions in complete growth medium: DMEM/F12 with 10% 
fetal bovine serum (FBS) (lot no. 40F6120K; Gibco, Vienna, 
Austria), 2 mM L-glutamine, 100 U/mL penicillin and strepto-
mycin, and 1 ng/mL amphotericin B (Sigma-Aldrich, Vienna, 
Austria) until passage 4–6. FACS analysis showed the follow-
ing surface protein expression pattern to be characteristic of 
hMSCs used in the experiment (Kulterer et al. 2007): CD14–, 
CD29+, CD34–, CD44+, CD45–, CD49e+, CD105+, CD166+, 
without  any  significant  quantitative  differences  between 
donors (Serotec, Vienna, Austria).
Custom-made silastic dishes were preconditioned with stan-
dard growth medium, washed twice with PBS, and coated with 
fibronectin (5 µg/mL in PBS; PAA, Pasching, Austria) for 20 
min at room temperature. hMSCs were plated at a cell density 
of 1 × 104 cells per cm2 after careful washing. The cells were 
allowed to attach overnight in growth medium supplemented 
with 0.05 mM L-ascorbic acid 2-phosphate (Sigma-Aldrich, 
Vienna, Austria) before starting CTS. The same procedure 
without the application of cyclic tensile strain was performed 
simultaneously in controls (CON).
CTS was applied with a computerized custom-made 4-point 
bending device (Bottlang et al. 1997) (Cell Strain Unit ver-
sion 3.0, University of Iowa, IA), as tensile strains of less than 
4,000 µstrain have been shown to be related to the level asso-
ciated with the physiological process of bone (re)modeling 
(Murray and Rushton 1990). The following straining protocol 
was used: 1,000 cycles (1 Hz) of sawtooth-shaped uniaxial 
tensile strain with a maximum of 3,000 µstrain, 6 times a day 
for a total period of 72 h. Culture medium was changed on 
day 2 and any appearance of non-adherent cells was checked 
by careful examination of the supernatant by light microscopy. 
All measurements started immediately after the last straining 
cycle and they were performed at least in triplicate.
Cell proliferation and cell viability 
Cell viability was tested with the XTT assay (Cell Prolifera-
tion Kit II; Roche Diagnostics, Mannheim, Germany) without 
detaching the cells, following the manufacturer’s instructions. 
In addition, resuspended cells were stained with trypan blue, 
and at least 100 viable cells were counted in duplicate by two 
independent investigators using a hemocytometer. No signifi-Acta Orthopaedica 2009; 80 (4): 491–498  493
cant differences were found in cell viability between strained 
and unstrained hMSCs (86% (SD 10) and 89%, (SD 8.5), 
respectively). 
Analysis of mRNA expression by real-time RT-PCR
After completion of the last training cycle, total RNA isola-
tion was started immediately using the Aqua Pure RNA Isola-
tion Kit (Bio-Rad, Vienna, Austria) according to the manu-
facturer’s instructions. RT-PCR was performed as previously 
described (Friedl et al. 2007). Briefly, reverse transcription 
was carried out after treatment with DNAse I (Sigma-Aldrich, 
Vienna, Austria) using the 1st Strand cDNA Synthesis Kit 
(Roche Diagnostics, Mannheim, Germany) with random hex-
amer primers reverse transcription. Negative controls were set 
up without RNA templates and without reverse transcriptase 
(AMV). Preparations of cDNA were checked by spectropho-
tometry (at A260 and A280) and by gel electrophoresis. The 
PCR primers (TIB-Molbiol, Berlin, Austria) used, the product 
length, and estimated melting temperatures are listed in Table 
1. Real-time PCR was run in a LightCycler Instrument (Roche, 
Germany) using the FastStart DNA Master SYBR Green I Kit 
(Roche  Diagnostics,  Mannheim,  Germany)  with  an  initial 
activation of the FastStart Taq polymerase at 95°C for 10 min. 
Amplification conditions were 35 cycles of annealing at 56–
58°C for 7 seconds followed by an extension phase at 72°C for 
7–9 seconds. The PCR products were visualized by agarose 
gel electrophoresis and sequenced by fluorescent automated 
sequencing (Beckman model CEQ8000, software version 5-
0.345). The relative changes in gene expression were deter-
mined by the 2-∆∆CT method as described in detail by Livak 
and Schmittgen (2001). Normalization was performed to the 
mRNA level of clathrin (CLCT) and B2M, which produced 
essentially the same results. 
Alkaline phosphatase (ALP) activity
ALP activity was measured with standard protocols for con-
version of p-nitrophenyl phosphate (p-NPP) to p-nitrophenol 
(p-NP) (Sigma Kit 104, Vienna, Austria). Cells were lysed 
with  0.5%  Triton  X-100  (Sigma-Aldrich,  Vienna, Austria) 
after triple washing with Tyrode’s balanced salt solution, and 
lysates were incubated with 360 µM p-NPP in 0.75 M ALP 
buffer (pH 10.3) at 37°C. Quantification of p-NP was carried 
out kinetically within a linear range for 10 min at 405 nm using 
a p-NP standard absorption curve. Diluted FBS was used as 
positive control. Measurements were performed in triplicate 
for each of three 2.8-cm2 wells, and the mean values were 
used for calculations. Results are expressed either as µmol p-
NP/min per well (µM/min) or as cell-based values by normal-
izing to cell numbers (µM/min/106 cells). 
Bone marrow plasma measurements
Biochemical measurements were performed on bone marrow 
plasma because it constitutes the humoral microenvironment 
of hMSCs in vivo. Fasting plasma was isolated by centrifuga-
tion of heparinized bone marrow aspirates and it was stored at 
–80°C until use. 
All measurements including triglycerides, cholesterol, glu-
cose 17β-estradiol (Adaltis, Bologna, Italy), leptin (Diagnostic 
System Laboratories, Sinsheim, Germany), resistin and adi-
ponectin (R&D Systems, distributed by Biomedica Gruppe, 
Vienna, Austria), CrossLaps (Nordic Bioscience Diagnostic, 
Herlev, Denmark), osteocalcin (CIS bio international, Gif-sur-
Yvette  Cedex,  France),  osteoprotegerin  (Immunodiagnostic 
Systems Ltd., Boldon, UK), insulin-like growth factor I (IGF-
Table 1. Primers used for real-time RT-PCR
Symbol                 Gene name  Accession no.  Primer sequence  Amplicon  MT (°C) 
                      size (bp)   
CLTC  clathrin, heavy polypeptide (Hc)  X55878  5’-AGAAACTGCATGGAGGCACAA  165  81
      3’-TGGGGCTGACCATAAACAATG   
B2M  beta-2-microglobulin  AB021288  5’-GCTATCCAGCGTACTCCAAAGA  102  80
      3’-GGATGGATGAAACCCAGACA   
COL1A1  collagen, type I, alpha 1  Z74615  5’-CGAAGACATCCCACCAATCAC  250  92
      3’-TCCCTTGGGTCCCTCGAC   
MKI67  antigen identified by monoclonal antibody Ki-67   X65550  5’-GCCTGTACGGCTAAAACATGGA  182  82
      3’-TTGAGGAGAGGCAGGGTGAA   
RUNX2  runt-related transcription factor 2  AF001443  5’-ACAGTAGATGGACCTCGGGAAC  82  83
      3’-TGAGGCGGTCAGAGAACAAA   
ALPL  alkaline phosphatase, liver/bone/kidney   NM_000478  5’-CCTGGACCTCGTTGACACCT  136  86
      3’-GTCCCCTGGCTCGAAGAGA   
SPARC  secreted protein, acidic, cysteine-rich (osteonectin)  J03040  5’-TGCCACTGAGGGTTCCCA  211  88 
      3’-TCGGTTTCCTCTGCACCATC   
SPP1  secreted phosphoprotein 1 (osteopontin,   NM_000582  5’-AACGCCGACCAAGGAAAACT  150  84
  bone sialoprotein I, early T-lymphocyte activation 1)    3’-GGCCACAGCATCTGGGTATT     
COL2A1  Collagen, type II, alpha1  MN_001844  5’-ATGCTGGTCCTCAAGGCAAA  196  93
      3’-CCAGGAAGACCCCTCAGACC 
CSPCP  Homo sapiens aggrecan  MN_001135  5’-CGAGGAGCAGGAGTTTGTCA116  87
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I), intact parathyroid hormone [1-84], and human growth hor-
mone (all R&D Systems, Biomedica Gruppe, Vienna, Austria) 
were  performed  by  the  central  laboratory  core  unit  of  the 
university hospital in duplicate; mean values were used for 
analysis. 
Data analysis
Deviations from normal distribution were tested with the Kol-
mogorov-Smirnov test. Statistical analyses were performed 
with  the  paired-samples  t-test,  differential  gene  expression 
was analyzed with the Wilcoxon signed-ranks test, and corre-
lations were tested by Pearson r statistics. Possible differences 
between female and male donors were analyzed by two-way 
ANOVA analysis, and values are presented as either mean 
(with SEM or SD) or median value with corresponding con-
fidence interval as appropriate. All statistics were performed 
with SigmaStat version 2.03.0 (SPSS Inc.) and results were 
considered significant at p < 0.05. 
Results
Donor and baseline characteristics
5 female donors (f, aged 65 (SD 13) years) and 5 male donors 
(m, aged 67 (SD 17) years) with a mean body mass index 
(BMI) of 30 (SD 6.0) kg/m2 were included (Table 2). In our 
cohort, donor’s age was significantly associated with leptin 
levels (r = 0.67, p < 0.05) and tended to be inversely related 
to human growth hormone levels (r = –0.62, p = 0.06). While 
there was a weak trend of an association between donor’s age 
and BMI (r = 0.51, p = 0.1), there was a significant correla-
tion between the latter and plasma leptin levels (r = 0.81, p 
= 0.0001) and an inverse correlation with IGF-I levels (r  = 
–0.77,  p  =  0.007).  No  significant  correlations  were  found 
between the anthropomorphometric characteristics and any of 
the other indices listed in Table 4.
Biochemical and molecular characteristics of 
unstrained hMSCs (CON) 
Cell-based ALP activity ranged between 0.89 and 17 µM/
min/106 cells (mean 6.2 (SD 5.0) µM/min/106) in control 
hMSCs (CON), while donor-to-donor variability in marker 
gene expression showed differences of up to 48 fold in the 
message levels of mRNA. There were no significant correla-
tions between the genotypic or phenotypic characteristics 
of control hMSCs and any of the donor-specific parameters 
listed in Table 4 (including gender; data not shown). 
Effects of cyclic tensile strain (CTS) 
The early osteogenic marker genes were all significantly upreg-
ulated due to CTS: i.e. RUNX2 (1.9-fold), ALPL (2.7-fold), 
SPARC (4.2-fold), SPP1 (2.8-fold). COL1A1 expression was 
also significantly enhanced (3.5-fold), while the median value 
of the messages of cell cycle-related antigen Ki67 tended to be 
decreased (Table 3). This was accompanied by an increase in 
cell-based ALP activity (mean: plus 40% (SD 24); p < 0.01) 
(Figure 1). Cell density was lower following CTS compared 
with CON (mean: minus 20% (SD 15), p = 0.02; Figure 1), 
which was similar to the changes found in cell viability tested by 
Table 2. Characteristics of donors 5 female and 5 male donors matched for age were included consecutively and bone marrow-derived 
human mesenchymal stem cells (hMSCs) from passage no. (p) 4–6 were used for in vitro experiments
Donor  Sex  Age  BMI  Diagnosis   Surgery  hMSCs
  01  f  53  18.7  Osteoarthritis hip  Total hip arthroplasty   p5 
  02  f  77  25.6  Osteoarthritis hip  Total hip arthroplasty  p4 
  03  f  64  35.3  TJR hip – aseptic loosening   Revision of cup  p4 
  04  m  73  24.2  Osteoarthritis knee  Total hip arthroplasty  p6 
  05  m  81  30.0  Osteoarthritis hip  Total hip arthroplasty  p4 
  06  m  39  23.3  Idiopathic scoliosis  Scoliosis correction surgery  p4 
  07  m  75  37.6  TJR hip – aseptic loosening   Revision of stem  p4 
  08  f  78  32.9  TJR knee – aseptic loosening  Revision, exchange of tibial component   p4 
  09  m  68  25.8  Osteoarthritis hip  Total hip arthroplasty  p4 
  10  f  52  25.9  Osteoarthritis hip  Total hip arthroplasty  p4
Table 3. Genotypic effects of cyclic tensile strain (CTS) on hMSCs. 
Differential  gene  expression  for  cell  cycle-specific  nuclear  anti-
gen Ki67 (MKI67), collagen type I (COL1A1), alkaline phosphatase 
(ALPL),  runt-related  transcription  factor  2  (RUNX2),  osteonectin 
(SPARC), and osteopontin (SPP1) was determined by real-time RT-
PCR in unstrained (CON) and strained (CTS) hMSCs. 
  Log2 – Ratio (CTS/CTR)
  Median  95 % CI  p-value  X-fold
MKI67  -0.74  –2.03–1.15  0.51  0.4
COL1A1  1.80    1.15–2.25  0.01  3.5
ALPL  1.27    0.28–1.85  0.02  2.4
RUNX2  0.94    0.25–1.53  0.02  1.9
SPARC  2.04    1.30–2.32  0.004  4.1
SPP1  1.48    1.12–2.00  0.005  2.8Acta Orthopaedica 2009; 80 (4): 491–498  495
XTT assay (minus 18% (SD 18), p < 0.05). As a consequence, 
the phenotypic osteogenic response in terms of cell-based ALP 
activity and cell numbers (µM/min) was not statistically sig-
nificantly altered by CTS on average (mean: plus 11% (SD 29), 
p = 0.3), but ranged widely between minus 31% and plus 60% 
(Figure 1). No significant sex differences were found in any of 
the variables mentioned previously.
Table 4. Physiology of donors and the phenotypic mechanoresponse of hMSCs. Possible relationships between   
donor’s physiology, characterized by (A) anthropomorphometric and (B) biochemical variables and the phenotypic 
characteristics in terms of ALP activity of unstrained hMSCs (CTR, raw data) as well as the response to cyclic tensile 
strain in terms of relative change of ALP activity were determined by linear correlation analysis. 
  Pearson  r
Donor’s physiology  Mean value (SEM)  ALP (CTR)  Relative change 
     (µM/min)  of ALP (CTS/CTR) a
  
Antropomorphometric characteristics         
  Age  (years)  66 (4.4)  f:    65 (5.6)    0.49 (p=0.2)  –0.56 (p=0.1)
        m:  67 (7.4)       
  BW  (kg)  74 (4.9)  f:    68 (4.2)    0.49 (p=0.2)  –0.78 (p=0.006)
        m:  81 (6.9)      
  BMI  (kg/m2)  28 (1.9)  f:    28 (2.9)    0.25 (p=0.7)  –0.91 (p<0.001)
        m:  28 (2.6)       
Biochemical characteristics          
  Bone metabolism         
    Osteocalcin  (ng/mL)  10.6 (1.4) a        0.06 (p=0.9)  –0.13 (p=0.7) 
    Cross laps  (pmol/L)  4049 (955)    –0.01 (p=1)  –0.01 (p=1) 
    Parathyroid hormone (pg/mL)  27.1 (3.3)      0.43 (p=0.2)  –0.34 (p=0.4) 
    Insulin-like growth factor-I  (ng/mL)  137.4 (30)      0.59 (p=0.1)    0.57 (p=0.2) 
    Human growth hormone (ng/mL)  1.20 (0.69)    –0.13 (p=0.7)    0.35 (p=0.3) 
  Fat metabolism         
    Triglycerides  (mg/dL)  405 (162)    –0.11 (p=0.8)     0.33 (p=0.4) 
    Cholesterin  (mg/dL)  137 (15.7)    –0.12 (p=0.8)    0.33 (p=0.4) 
    Glucose (mg/dL)  84.2 (9.4)    –0.21 (p=0.6)  –0.43 (p=0.3)) 
    Leptin  (ng/mL)  8.3 (2.4)      0.05 (p=0.9)  –0.68 (p=0.04) 
    Adiponectin  (ng/mL)  5729 (779)      0.14 (p=0.7)  –0.51 (p=0.2) 
    Resistin  (ng/mL)  76.0 (14.4)      0.66 (p=0.05)    0.03 (p=0.9) 
    Estradiol  (pg/mL)  13.5 (3.7)    –0.23 (p=0.6)    0.67 (p=0.05)
         
a  Osteocalcin: female 7.8 (1.8) ng/mL, male 12.9 (1.5) ng/mL; p = 0.04 
0.6
0.8
1.0
1.2
1.4
1.6
1.8
ALP (µM/min)
0.6
0.8
1.0
1.2
1.4
1.6
1.8
Cell-density ALP (µM/min/106)
    p=0.3
  p=0.02
 p=0.003
A B
Relative change (CTS/CTR) [1] Relative change (CTS/CTS) [1]
Figure 1. Osteogenic response of hMSCs to mechanical strain. 
A. The phenotypic response expressed as relative change in ALP activity between unstrained 
(CTR) and strained (CTS) hMSCs at a culture-well based level (µM/min) accounts for both. 
B. The effects on cell-density and cell-based ALP activity. Dashed lines show mean values. 496  Acta Orthopaedica 2009; 80 (4): 491–498
Donor-specific mechano-response of hMSCs
While no statistically significant correlations were found with 
any of the determined parameters in strained or unstrained as 
referred to in Ta ble 4  hMSCs (raw data), there was a correla-
tion between the phenotypic ALP response (i.e. per cent rela-
tive change between CTS and CON) and the donor’s anthro-
pomorphometric characteristics BMI (r = –0.91, p < 0.001) 
and BW (r = –0.78, p = 0.006) (Table 4A). This mechano-
response was also found to be related to fasting levels of leptin 
(r = –0.68, p = 0.04) and estradiol (r = 0.67, p = 0.05), while 
all other indices of bone (i.e. osteocalcin, CrossLaps, insulin-
like growth factor I, parathyroid hormone, and human growth 
hormone) and fat metabolism (i.e. triglycerides, cholesterin, 
glucose, adiponectin, and resistin) did not appear to be signifi-
cantly correlated to the osteogenic mechano-response (Table 
4B). Furthermore, no significant relationship was found at the 
gene expression level between the physiological characteris-
tics of the donor and the functional characteristics of hMSCs, 
either in CON and CTS (raw data) or in strain-related changes 
(data not shown). 
Donor’s age, obesity, and the mechano-response of 
hMSCs 
There was an inverse correlation between the CTS response = 
relative change (CTS/CTR) in cell-density and donor’s age (r 
= –0.71, p = 0.02), but age did not affect the cell-based ALP 
activity (r = –0.05, p = 0.9). While there was only a trend of 
reduced phenotypic osteogenic mechano-response with age (r 
= –0.56, p = 0.1) (Table 4A), this was less in obese patients 
than in non-obese patients (p = 0.01) (Figure 2B). 
Discussion
The importance of physical factors in the development and 
maintenance of bone tissue has been recognized for many 
years  (Harada  and  Rodan  2003)  and  it  has  been  convinc-
ingly shown that bone cells are sensitive to physical stimuli. 
Recently, tensile forces of up to 4,300 µstrain were reported to 
support osteogenic differentiation of hMSCs under appropriate 
culture conditions (Mirza et al. 2007), which is in accordance 
with our findings, where cyclic tensile strain of up to 3,000 
µstrain was sufficient to initiate an osteogenic stimulus at the 
gene expression level and at the level of ALP activity (Table 3 
and Figure 1). With regard to biological regeneration, cell dif-
ferentiation and the number of cells are the critical factors for 
an appropriate response, and—since CTS affected both fac-
tors—the phenotypic osteogenic response to CTS may be best 
reflected by ALP activity at the culture-well level (µM/min). 
Interestingly, the hMSCs did not respond well to mechanical 
strain in some of the patients, while this osteogenic response 
was quite pronounced in others. Most importantly, this vari-
ability was found to be highly related to the BMI of the donor 
(Figure 2).
The  pronounced  intrinsic  heterogeneity  of  multipotent 
hMSCs is well known and is thought to represent the lineage 
hierarchy, where some of the cells are multipotent stem cells 
while others are more restricted primitive progenitor cells of 
several cell lineages at various stages of differentiation (Aubin 
and Triffitt 2002). Thus, it might be speculated that the BMI-
related mechano-response we found may be due to a commit-
ment of hMSCs independently of CTS, for example, simply 
due to the number of fat cells in the culture of obese patients. 
However, this can be ruled out for several reasons: it is very 
unlikely that cells at passage 4–6 cells would be committed in 
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Figure 2. Relationship between the phenotypic mechanoresponse of hMSCs and donor’s body mass index (BMI)
A. The mechanoresponse in terms of the relative change in ALP activity (µM/min) between unstrained (CTR) and strained 
(CTS) hMSCs was a function of donor’s BMI (r=-0.91, p<0.001).
B. This was significantly altered in obese (n=4) compared with non-obese (n=6) patients. Dashed lines show mean (CTR) 
values.
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a cell-specific differentiation pathway. This has been convinc-
ingly demonstrated by large-scale gene expression analyses 
(Tremain et al. 2001, Kulterer et al. 2007, Scheideler et al. 
2008) and is further supported by the fact that we detected 
no messages for adipo- or chondrocytic markers (i.e. CSPCP 
and COL2A1) in CON and CTS. Most importantly, due to the 
study design, any commitment independent of CTS would 
also have affected the hMSCs in CON; but none of the geno-
typic and phenotypic parameters in CTS and CON (raw data) 
were related to the mechano-response as determined by paired 
analysis, or were significantly correlated to any of the donor’s 
physiological  characteristics  (Table  4).  Consequently,  our 
findings  suggest  that  physiological  factors  associated  with 
donor’s BMI may not necessarily affect the overall osteogenic 
potential of hMSCs, but will severely hamper the osteogenic 
response of hMSCs to mechanical strain, which may be of 
clinical importance. 
It is well established that mechanical forces are major deter-
minants of bone mass (Harada and Rodan 2003). Although 
absolute bone density is known to be higher in obese indi-
viduals, it has been demonstrated that when adjusted for body 
weight, these individuals suffer lower relative bone area and 
bone mass than non-obese individuals (Goulding et al. 2000), 
which may also be responsible for a paradoxical increase in 
fracture risk (Strotmeyer et al. 2005). This is in accordance 
with previous findings (Weiler et al. 2000), which showed that 
body fat (relative to weight) negatively influenced bone min-
eral content and bone density during growth, thus compromis-
ing the attainment of peak bone mass. In addition, there is 
evidence of increased risk of implant failure after lower limb 
joint surgery in obese patients, particularly after total joint 
replacement of the knee (Winiarsky et al. 1998, Foran et al. 
2004, Berend et al. 2005, Amin et al. 2006). 
It  is  important  to  consider  that  all  hMSC  samples  were 
isolated from bone marrow at the iliac crest. Thus, it seems 
unlikely  that  local  conditions  related  to  primary  diagnosis 
indicating the need for elective surgery would account directly 
for the mechano-resistance in our cohort. Indeed, the process 
of aging as well as obesity itself are accompanied by multiple 
changes in an individual’s whole body physiology, whereas 
each of them has the potential to severely affect the functional 
properties of hMSCs within the marrow “stem cell niche” 
(Caplan et al. 1998). Although interpretation of the data may 
be limited due to the small sample size, some of the results 
found from correlation analysis are quite coherent and pro-
vide  some  tentative  suggestions  regarding  this  challenging 
issue. Indeed, adipose tissue is being increasingly recognized 
as a secretory organ that releases bioactive peptides known to 
affect a number of physiological functions in bone metabo-
lism also. As expected, fasting leptin levels correlated with 
BMI, but were also inversely related to the phenotypic ALP 
response (Table 4), which contrasts with previous findings that 
leptin is capable of directly stimulating osteoblast differentia-
tion via leptin receptors (Thomas and Martin 2005). Hence, 
the inverse correlation between the CTS response and leptin 
levels is likely to reflect its co-linearity with BMI. Based on 
our findings, the adipokines adiponectin and resistin cannot 
be attributed to the BMI-linked mechano-response too, but a 
weak direct correlation was found with the levels of 17β-estra-
diol. This is an interesting finding because estrogen is known 
to be a strong determinant of bone mass in both women and 
men, and has been convincingly shown in vitro and in vivo 
to critically mediate mechanostimulatory effects via estrogen 
receptor (ER)-alpha (Lee et al. 2003). However, the correla-
tion with the osteogenic mechano-response was weak; thus, as 
yet unknown variables related to the donor’s fat metabolism 
are likely to play crucial roles in the impaired responsiveness 
of hMSCs to mechanical stimuli. 
While our study was designed with a view to exclusion 
of covariate factors beyond mechanical straining, we should 
mention that weak associations may be easily missed due to 
the sample size and the intrinsic variability of undifferenti-
ated hMSCs. Although causality cannot be proved by corre-
lation analysis, the finding that the variability in genotypic 
and phenotypic characteristics of hMSCs was not related to 
BMI—while this was a strong predictor of the phenotypic 
osteogenic mechano-response under controlled in vitro condi-
tions—is strongly suggestive of a systemically upstream pro-
cess of imprinting of hMSCs within the donor’s marrow stem 
cell niche. For this, further investigation is necessary, since 
obesity-related mechano-resistance of hMSCs may possibly 
be of clinical significance for disturbances in bone metabo-
lism, bone-healing, and the risk of implant failure. 
GF and RW defined the hypothesis and designed the study. HS was respon-
sible for the molecular part of the study and RA was responsible for the bio-
chemical part. 
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